华森制药: 2025年半年度报告摘要

Core Viewpoint - The report highlights the financial performance of Chongqing Huason Pharmaceutical Co., Ltd. for the first half of 2025, showing an increase in revenue and net profit compared to the same period last year, alongside a proposed cash dividend distribution to shareholders [1][2]. Financial Performance - The operating revenue for the reporting period is approximately 441.91 million yuan [2]. - The net profit attributable to shareholders is approximately 53.95 million yuan, representing a year-on-year increase of 14.27% from 47.21 million yuan [2]. - The net profit after deducting non-recurring gains and losses is approximately 41.79 million yuan, reflecting a growth of 5.76% compared to the previous year [2]. Cash Flow and Earnings - The net cash flow from operating activities is approximately 27.53 million yuan, which is a decrease of 57.49% from 64.76 million yuan in the previous year [3]. - Basic earnings per share are reported at 0.1292 yuan, an increase of 14.24% from 0.1131 yuan [3]. - The diluted earnings per share are also 0.1292 yuan, showing the same percentage increase [3]. Asset and Equity Position - Total assets at the end of the reporting period amount to approximately 2.02 billion yuan, marking a 5.38% increase from 1.92 billion yuan at the end of the previous year [3]. - The net assets attributable to shareholders are approximately 1.68 billion yuan, which is a 1.49% increase from 1.66 billion yuan [3]. Shareholder Information - The top shareholder, Chengdu Dijiang, holds 17.34% of the shares, followed by Wang Ying with 8.76% and Liu Xiaoying with 8.60% [4]. - The report indicates that there are no changes in the controlling shareholder or actual controller during the reporting period [5].